Verona Pharma plc
VRNA
Ранг среди акций
#2227
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Цена акции
$106.91
Последняя синхронизация: 2025-10-07
Рыночная капитализация
$9.09B
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
GB
Торговля Verona Pharma plc (VRNA)
Категория
Healthcare
Прибыль Verona Pharma plc (VRNA)
Прибыль на Jun 2025 TTM: $-56.52M
Согласно последним финансовым отчетам Verona Pharma plc, текущая прибыль компании составляет $-56.52M. В 2023 году компания получила прибыль $-42.28M, больше, чем прибыли за 2022, которая составила $-56.62M. Отображаемая прибыль на этой странице — это прибыль до уплаты процентов и налогов, или просто EBIT.
История прибыли компании Verona Pharma plc с 2005 по 2026
Прибыль в конце каждого года
| Год | Прибыль | Изменить |
|---|---|---|
| 2026 (TTM) | $-56.52M | -56.62% |
| 2024 | $-130.30M | 208.20% |
| 2023 | $-42.28M | -25.33% |
| 2022 | $-56.62M | 37.75% |
| 2021 | $-41.10M | -13.52% |
| 2020 | $-47.53M | 17.27% |
| 2019 | $-40.53M | 31.86% |
| 2018 | $-30.74M | -9.75% |
| 2017 | $-34.06M | 362.02% |
| 2016 | $-7.37M | -44.44% |
| 2015 | $-13.27M | 126.33% |
| 2014 | $-5.86M | 25.78% |
| 2013 | $-4.66M | 75.08% |
| 2012 | $-2.66M | -40.09% |
| 2011 | $-4.44M | -2.04% |
| 2010 | $-4.54M | 8.38% |
| 2009 | $-4.18M | 45.74% |
| 2008 | $-2.87M | -40.29% |
| 2007 | $-4.81M | 105.89% |
| 2006 | $-2.34M | -3,133.92% |
| 2005 | $76.99K | 0.00% |
Прибыль схожих компаний или конкурентов
| Компания | Прибыль | Разница в прибыли | Страна |
|---|---|---|---|
| $5.27B | -9,432.91% |
US
|
|
| $-3.09B | 5,361.85% |
US
|
|
| $-4.02B | 7,005.88% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,551.30% |
NL
|
